Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

Next Previous
Trial Profile

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium-68 FAP 2286-Clovis Oncology (Primary) ; Lutetium-177 FAP 2286 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LuMIERE
  • Sponsors Clovis Oncology [CEASED]; Novartis Pharmaceuticals

Most Recent Events

  • 14 Aug 2024 Status changed from active, no longer recruiting to recruiting.
  • 02 Feb 2024 Planned number of patients changed from 300 to 222.
  • 02 Feb 2024 Planned End Date changed from 1 Jun 2026 to 30 Jun 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top